News | May 06, 2025
OneSource Specialty Pharma reports consolidated Q4 FY25 PAT at Rs. 98.50 Cr
The company has posted net loss of Rs. 17.97 crores for the Financial Year ended March 31, 2025
The company has posted net loss of Rs. 17.97 crores for the Financial Year ended March 31, 2025
The inspection has concluded with four observations
These appointments align with the group’s philosophy of having a strong and independent board with exceptional industry experts, ensuring strategic guidance and effective governance
This approval marks a significant milestone in OneSource’s ongoing commitment to quality and regulatory compliance
OneSource operates five cGMP facilities and has a strong track record, with 138 successful regulatory and customer audits to date by all major regulatory bodies
The share subscription agreements are being executed at a pre-money equity value of US$ 1.65 billion
Aims to achieve CDMO sales of US$ 400 million by 2028
The company will now seek final approval from NCLT, Mumbai Bench, and upon its receipt, OneSource will proceed to seek listing approvals from the BSE and NSE
Revolutionary technology will further boost OneSource’s scientific services offerings
Subscribe To Our Newsletter & Stay Updated
